Skip to main content
Top
Published in: Neurological Sciences 6/2022

01-06-2022 | Spastic Paraplegia | Original Article

The second family affected with a PRDM8-related disease

Authors: Atefeh Davarzani, Amin Shahrokhi, Seyyed Saleh Hashemi, Aida Ghasemi, Mohammad Reza Habibi Kavashkohei, Niloofar Farboodi, Anthony E. Lang, Maryam Ghiasi, Mohammad Rohani, Afagh Alavi

Published in: Neurological Sciences | Issue 6/2022

Login to get access

Abstract

Introduction

Lafora disease (LD) is a severe form of progressive myoclonus epilepsy characterized by generalized seizures, myoclonus, intellectual decline, ataxia, spasticity, dysarthria, visual loss, and in later stages, psychosis and dementia. To date, mutations in the EPM2A and EPM2B/NHLRC1 genes have been identified as the common causes of LD. However, a mutation in PRDM8 has been reported only once in a Pakistani family affected with early-onset Lafora disease. In the present study, we report the second family with a PRDM8 mutation.

Methods

Two affected individuals of an Iranian family initially diagnosed as complicated hereditary spastic paraplegia (HSP) underwent careful neurologic examination. Homozygosity mapping and whole-exome sequencing were performed. Based on the results of genetic analysis to detection of Lafora bodies, a skin biopsy was done.

Results

The clinical features of the patients were described. Linkage to chromosome 4 and a mutation in the PRDM8 gene were identified, suggesting the patients may be affected with early-onset LD. However, like the Pakistani family, the search for Lafora bodies in their skin biopsies was negative. Their electroencephalograms showed generalized epileptiform discharges in the absence of clinical seizures.

Conclusions

The current study increases the number of PRDM8-related cases and expands the phenotypic spectrum of mutations in the PRDM8 gene. Both reported PRDM8-related families presented intra and inter-familial heterogeneity and they have originated from the Middle East. Thus, it seems the PRDM8 mutations should be considered not only in LD but also in other neurodegenerative disorders such as a complicated HSP-like phenotype, especially in this region.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jansen AC, Andermann E (2019) Progressive myoclonus epilepsy, Lafora type, GeneReviews®[Internet]. University of Washington, Seattle Jansen AC, Andermann E (2019) Progressive myoclonus epilepsy, Lafora type, GeneReviews®[Internet]. University of Washington, Seattle
3.
go back to reference Minassian BA (2001) Lafora’s disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 25(1):21–29CrossRef Minassian BA (2001) Lafora’s disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 25(1):21–29CrossRef
4.
go back to reference Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, Criado-García O, Fernandez-Sanchez E, Medraño-Fernández I, Domínguez J (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10(11):1407–1413CrossRef Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, Criado-García O, Fernandez-Sanchez E, Medraño-Fernández I, Domínguez J (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10(11):1407–1413CrossRef
5.
go back to reference Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA (2018) Lafora disease—from pathogenesis to treatment strategies. Nat Rev Neurol 14(10):606–617CrossRef Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA (2018) Lafora disease—from pathogenesis to treatment strategies. Nat Rev Neurol 14(10):606–617CrossRef
6.
go back to reference Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BAJNRN (2018) Lafora disease—from pathogenesis to treatment strategies. Nat Rev Neurol 14(10):606–617CrossRef Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BAJNRN (2018) Lafora disease—from pathogenesis to treatment strategies. Nat Rev Neurol 14(10):606–617CrossRef
7.
go back to reference Delgado-Escueta A, Ganesh S, Yamakawa K (2001) Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet 106(2):129–138CrossRef Delgado-Escueta A, Ganesh S, Yamakawa K (2001) Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet 106(2):129–138CrossRef
8.
go back to reference Brewer MK, Putaux J-L, Rondon A, Uittenbogaard A, Sullivan MA, Gentry MS (2020) Polyglucosan body structure in Lafora disease. Carbohydr Polym 240:116260CrossRef Brewer MK, Putaux J-L, Rondon A, Uittenbogaard A, Sullivan MA, Gentry MS (2020) Polyglucosan body structure in Lafora disease. Carbohydr Polym 240:116260CrossRef
9.
go back to reference Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS (2012) Glycogen and its metabolism: some new developments and old themes. Biochem J 441(3):763–787CrossRef Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS (2012) Glycogen and its metabolism: some new developments and old themes. Biochem J 441(3):763–787CrossRef
10.
go back to reference Delgado-Escueta AV (2007) Advances in lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep 7(5):428–433CrossRef Delgado-Escueta AV (2007) Advances in lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep 7(5):428–433CrossRef
11.
go back to reference Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, Minassian BA, DePaoli-Roach AA, Roach PJ (2008) Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J Biol Chem 283(49):33816–33825CrossRef Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, Minassian BA, DePaoli-Roach AA, Roach PJ (2008) Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J Biol Chem 283(49):33816–33825CrossRef
12.
go back to reference Turnbull J, Girard J-M, Lohi H, Chan EM, Wang P, Tiberia E, Omer S, Ahmed M, Bennett C, Chakrabarty A (2012) Early-onset Lafora body disease. Brain 135(9):2684–2698CrossRef Turnbull J, Girard J-M, Lohi H, Chan EM, Wang P, Tiberia E, Omer S, Ahmed M, Bennett C, Chakrabarty A (2012) Early-onset Lafora body disease. Brain 135(9):2684–2698CrossRef
13.
go back to reference Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJJNG (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35(2):125–127CrossRef Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJJNG (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35(2):125–127CrossRef
14.
go back to reference Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Piliguian M, Roach PJ, Wang P, Ackerley CA (2011) PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet 7(4):e1002037CrossRef Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Piliguian M, Roach PJ, Wang P, Ackerley CA (2011) PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet 7(4):e1002037CrossRef
15.
go back to reference Serratosa JM, Gómez-Garre P, Gallardo ME, Anta B, De Bernabé DB-V, Lindhout D, Augustijn PB, Tassinari CA, Michelucci R, Malafosse AJHMG (1999) A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 8(2):345–352CrossRef Serratosa JM, Gómez-Garre P, Gallardo ME, Anta B, De Bernabé DB-V, Lindhout D, Augustijn PB, Tassinari CA, Michelucci R, Malafosse AJHMG (1999) A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 8(2):345–352CrossRef
16.
go back to reference Chan E, Omer S, Ahmed M, Bridges L, Bennett C, Scherer S, Minassian BJN (2004) Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 63(3):565–567CrossRef Chan E, Omer S, Ahmed M, Bridges L, Bennett C, Scherer S, Minassian BJN (2004) Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 63(3):565–567CrossRef
17.
go back to reference Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, Akagi T, Gomi H, Suzuki T, Amano K (2002) Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 11(11):1251–1262CrossRef Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, Akagi T, Gomi H, Suzuki T, Amano K (2002) Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 11(11):1251–1262CrossRef
18.
go back to reference Nitschke F, Sullivan MA, Wang P, Zhao X, Chown EE, Perri AM, Israelian L, Juana-López L, Bovolenta P, Rodríguez de Córdoba S (2017) Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease. EMBO Mol Med 9(7):906–917CrossRef Nitschke F, Sullivan MA, Wang P, Zhao X, Chown EE, Perri AM, Israelian L, Juana-López L, Bovolenta P, Rodríguez de Córdoba S (2017) Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease. EMBO Mol Med 9(7):906–917CrossRef
19.
go back to reference Singh S, Satishchandra P, Shankar SK, Ganesh S (2008) Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum Mutat 29(6):E1–E12CrossRef Singh S, Satishchandra P, Shankar SK, Ganesh S (2008) Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum Mutat 29(6):E1–E12CrossRef
21.
go back to reference Inoue M, Kuroda T, Honda A, Komabayashi-Suzuki M, Komai T, Shinkai Y, Mizutani K-I (2014) Prdm8 regulates the morphological transition at multipolar phase during neocortical development. PLoS One 9(1):e86356CrossRef Inoue M, Kuroda T, Honda A, Komabayashi-Suzuki M, Komai T, Shinkai Y, Mizutani K-I (2014) Prdm8 regulates the morphological transition at multipolar phase during neocortical development. PLoS One 9(1):e86356CrossRef
22.
go back to reference Jung CC, Atan D, Ng D, Ploder L, Ross SE, Klein M, Birch DG, Diez E, McInnes RR (2015) Transcription factor PRDM8 is required for rod bipolar and type 2 OFF-cone bipolar cell survival and amacrine subtype identity. Proc Natl Acad Sci 112(23):E3010–E3019CrossRef Jung CC, Atan D, Ng D, Ploder L, Ross SE, Klein M, Birch DG, Diez E, McInnes RR (2015) Transcription factor PRDM8 is required for rod bipolar and type 2 OFF-cone bipolar cell survival and amacrine subtype identity. Proc Natl Acad Sci 112(23):E3010–E3019CrossRef
23.
go back to reference Orouji E, Peitsch WK, Orouji A, Houben R, Utikal J (2020) Unique role of histone methyltransferase PRDM8 in the tumorigenesis of virus-negative Merkel cell carcinoma. Cancers 12(4):1057CrossRef Orouji E, Peitsch WK, Orouji A, Houben R, Utikal J (2020) Unique role of histone methyltransferase PRDM8 in the tumorigenesis of virus-negative Merkel cell carcinoma. Cancers 12(4):1057CrossRef
24.
go back to reference Park J, Kwon SO, Kim S-H, Kim SJ, Koh EJ, Won S, Kim WJ, Hwang SY (2020) Methylation quantitative trait loci analysis in Korean exposome study. Mol Cell Toxicol 16:175–183CrossRef Park J, Kwon SO, Kim S-H, Kim SJ, Koh EJ, Won S, Kim WJ, Hwang SY (2020) Methylation quantitative trait loci analysis in Korean exposome study. Mol Cell Toxicol 16:175–183CrossRef
25.
go back to reference Neidhart M, Pajak A, Laskari K, Riksen NP, Joosten LA, Netea MG, Lutgens E, Stroes ES, Ciurea A, Distler O (2019) Oligomeric S100A4 is associated with monocyte innate immune memory and bypass of tolerance to subsequent stimulation with lipopolysaccharides. Front Immunol 10:791CrossRef Neidhart M, Pajak A, Laskari K, Riksen NP, Joosten LA, Netea MG, Lutgens E, Stroes ES, Ciurea A, Distler O (2019) Oligomeric S100A4 is associated with monocyte innate immune memory and bypass of tolerance to subsequent stimulation with lipopolysaccharides. Front Immunol 10:791CrossRef
26.
go back to reference Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector EJGIM (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–423CrossRef Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector EJGIM (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–423CrossRef
27.
go back to reference Ferlazzo E, Canafoglia L, Michelucci R, Gambardella A, Gennaro E, Pasini E, Riguzzi P, Plasmati R, Volpi L, Labate A (2014) Mild L afora disease: clinical, neurophysiologic, and genetic findings. Epilepsia 55(12):e129–e133CrossRef Ferlazzo E, Canafoglia L, Michelucci R, Gambardella A, Gennaro E, Pasini E, Riguzzi P, Plasmati R, Volpi L, Labate A (2014) Mild L afora disease: clinical, neurophysiologic, and genetic findings. Epilepsia 55(12):e129–e133CrossRef
28.
go back to reference Ross SE, McCord AE, Jung C, Atan D, Mok SI, Hemberg M, Kim T-K, Salogiannis J, Hu L, Cohen SJN (2012) Bhlhb5 and Prdm8 form a repressor complex involved in neuronal circuit assembly. Neuron 73(2):292–303CrossRef Ross SE, McCord AE, Jung C, Atan D, Mok SI, Hemberg M, Kim T-K, Salogiannis J, Hu L, Cohen SJN (2012) Bhlhb5 and Prdm8 form a repressor complex involved in neuronal circuit assembly. Neuron 73(2):292–303CrossRef
Metadata
Title
The second family affected with a PRDM8-related disease
Authors
Atefeh Davarzani
Amin Shahrokhi
Seyyed Saleh Hashemi
Aida Ghasemi
Mohammad Reza Habibi Kavashkohei
Niloofar Farboodi
Anthony E. Lang
Maryam Ghiasi
Mohammad Rohani
Afagh Alavi
Publication date
01-06-2022
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 6/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05815-w

Other articles of this Issue 6/2022

Neurological Sciences 6/2022 Go to the issue